Idarubicin HCl is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL. Idarubicin is developed in an attempt to reduce the cardiotoxicity and enhance the therapeutic efficacy of the parent compound. Idarubicin HCl is an inhibitor of Topo II alpha and an apoptosis inducer. Idarubicin HCL was used at 0.1 nM - 10 nM in various cell-based in vitro assays.
